SG10201913300YA - Antitumoral compounds - Google Patents

Antitumoral compounds

Info

Publication number
SG10201913300YA
SG10201913300YA SG10201913300YA SG10201913300YA SG10201913300YA SG 10201913300Y A SG10201913300Y A SG 10201913300YA SG 10201913300Y A SG10201913300Y A SG 10201913300YA SG 10201913300Y A SG10201913300Y A SG 10201913300YA SG 10201913300Y A SG10201913300Y A SG 10201913300YA
Authority
SG
Singapore
Prior art keywords
antitumoral compounds
antitumoral
compounds
Prior art date
Application number
SG10201913300YA
Other languages
English (en)
Inventor
Marchante Maria Del Carmen Cuevas
Solloso Andres Francesch
Barrasa Valentin Martinez
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of SG10201913300YA publication Critical patent/SG10201913300YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
SG10201913300YA 2017-04-27 2018-04-27 Antitumoral compounds SG10201913300YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382228 2017-04-27
EP17382497 2017-07-26

Publications (1)

Publication Number Publication Date
SG10201913300YA true SG10201913300YA (en) 2020-03-30

Family

ID=62063080

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913300YA SG10201913300YA (en) 2017-04-27 2018-04-27 Antitumoral compounds
SG11201909841R SG11201909841RA (en) 2017-04-27 2018-04-27 Antitumoral compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201909841R SG11201909841RA (en) 2017-04-27 2018-04-27 Antitumoral compounds

Country Status (37)

Country Link
US (5) US11332480B2 (fr)
EP (5) EP3615544B9 (fr)
JP (5) JP7186723B2 (fr)
KR (3) KR102492283B1 (fr)
CN (4) CN114736219B (fr)
AU (4) AU2018260314C1 (fr)
BR (1) BR112019022282A2 (fr)
CA (1) CA3061518A1 (fr)
CL (1) CL2019003057A1 (fr)
CO (1) CO2019011967A2 (fr)
CY (3) CY1121885T1 (fr)
DK (5) DK3395821T3 (fr)
EC (1) ECSP19083967A (fr)
ES (5) ES2944344T3 (fr)
FI (3) FI4047002T3 (fr)
HK (2) HK1255941B (fr)
HR (5) HRP20230455T1 (fr)
HU (5) HUE046109T2 (fr)
IL (3) IL270153B2 (fr)
JO (1) JOP20190254A1 (fr)
LT (5) LT3395821T (fr)
MA (2) MA44021B1 (fr)
MD (5) MD4047002T2 (fr)
ME (2) ME03467B (fr)
MX (3) MX2019012812A (fr)
MY (1) MY198004A (fr)
PH (1) PH12019550224A1 (fr)
PL (5) PL3395821T3 (fr)
PT (2) PT3395821T (fr)
RS (5) RS59173B1 (fr)
SG (2) SG10201913300YA (fr)
SI (5) SI3615544T1 (fr)
TN (2) TN2019000211A1 (fr)
TW (3) TWI742273B (fr)
UY (1) UY37706A (fr)
WO (1) WO2018197663A1 (fr)
ZA (1) ZA201907119B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190254A1 (ar) * 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
JOP20220118A1 (ar) * 2019-11-21 2023-01-30 Pharma Mar Sa طرق لعلاج سرطان الرئة للخلايا الصغيرة بصيغ من لوربينيكتيدين
AU2021260792A1 (en) 2020-04-21 2022-11-24 Pharma Mar, S.A. Drug antibody conjugates
TW202144369A (zh) * 2020-04-26 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 海鞘素類衍生物及其製備方法與醫藥用途
IL308389A (en) 2021-05-19 2024-01-01 Pharma Mar Sa Dosing regimens for acubactadine

Family Cites Families (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3205220A (en) 1961-10-26 1965-09-07 Lilly Co Eli Leurosidine and leurocristine and their production
US4762949A (en) 1979-06-20 1988-08-09 University Of Illinois Foundation Acyl and carbamimidoyl alkanediamines
GB2058047B (en) 1979-07-11 1983-09-21 Asahi Chemical Ind Amides and amidines
FR2461995A1 (fr) 1979-07-20 1981-02-06 Lcc Cice Cie Europ Compo Elect Transducteur magneto-electrique pour systeme d'enregistrement magnetique, et systeme d'enregistrement comportant un tel transducteur
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
EP0048149B1 (fr) 1980-09-12 1983-11-30 University of Illinois Foundation Antibiotiques, dérivés de ceux-ci, procédé de leur extraction et compositions contenant ceux-ci
US5137870A (en) 1980-09-12 1992-08-11 The Board Of Trustees Of The University Of Illinois Didemnins and nordidemnins
US4782135A (en) 1980-09-12 1988-11-01 Board Of Trustees, University Of Illinois Composition of matter and process
US4548814A (en) 1980-12-18 1985-10-22 The Board Of Trustees Of The University Of Illinois Composition of matter and process
JPS5922518A (ja) 1982-07-29 1984-02-04 余合住金産業株式会社 洋服タンス
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4855086A (en) 1982-10-15 1989-08-08 Burroughs Wellcome Co. Novel pesticides, preparation and use
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
US4631149A (en) 1983-07-25 1986-12-23 University Of Illinois Antiviral eudistomins from a marine tunicate
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US4567253A (en) 1984-02-03 1986-01-28 Tony Durst 2-Substituted derivatives of podophyllotoxin and etoposide
JPS61109717A (ja) 1984-11-02 1986-05-28 Teruhiko Beppu 抗腫瘍剤
AU585936B2 (en) 1984-12-28 1989-06-29 Conpharm A.B. Pharmaceutically active podophyllotoxins
US4644072A (en) 1985-04-12 1987-02-17 Bristol-Myers Company Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof
DE3684868D1 (de) 1985-09-20 1992-05-21 Cernitin Sa Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
US4731377A (en) 1986-01-31 1988-03-15 Harbor Branch Oceanographic Institute, Inc. Antitumor cyclic peroxides
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
EP0309477B1 (fr) 1986-06-09 1991-11-06 The Board Of Trustees Of The University Of Illinois Ecteinascidines 729, 743, 745, 759a, 759b et 770
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4737510A (en) 1986-09-30 1988-04-12 The Board Of Trustees Of The University Of Illinois Bioactive metabolites from the caribbean sponge agelas coniferin
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US4847246A (en) 1987-09-11 1989-07-11 Wilson George R Antiviral compositions derived from fireflies and their methods of use
FR2623504B1 (fr) 1987-11-25 1990-03-09 Adir Nouveaux derives n-(vinblastinoyl-23) d'acide amino-1 methylphosphonique, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5559145A (en) 1988-06-01 1996-09-24 Oxaco S.A. 1,2,4-trioxane derivatives
ES2054011T3 (es) 1988-09-05 1994-08-01 Sankyo Co Un proceso para la preparacion de un compuesto, "leualacina".
WO1990005731A1 (fr) 1988-11-24 1990-05-31 University Of Queensland Macromolecules cytotoxiques
US5190876A (en) 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
CA2007507C (fr) 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine et n-methyl-sphingosine inhibiteurs de la croissance des cellules
US5583160A (en) 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US5053559A (en) 1989-12-29 1991-10-01 Oxaco S.A. Cleavage of 1,2,4-trioxanes
KR910014122A (ko) 1990-01-19 1991-08-31 디께다 가즈히꼬 에토포시드-2-디메틸아미노 화합물의 동결건조 제제
JPH0539283A (ja) 1991-01-31 1993-02-19 Suntory Ltd 新規物質Ｓ−５９９１７ａ及びその製造方法
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5336669A (en) 1991-12-10 1994-08-09 Erbamont, Inc. Cyclophosphamide monohydrate and lactose
JPH05247055A (ja) 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
GB9212000D0 (en) 1992-06-05 1992-07-15 Univ Madrid Complutense New synthetic antitumoral compound
KR950702994A (ko) 1992-08-12 1995-08-23 로렌스 티. 웰츠 탁솔과 복합된, 단백질 키나제 억제제 및 관련 화합물(protein kinase inhibitors and related compounds combined with taxol)
US5756734A (en) 1992-09-11 1998-05-26 Pharmamar, S.A. Crambescidins: new antiviral and cytotoxic compounds from the sponge crambe crambe
ES2059259B1 (es) 1992-09-22 1995-10-01 Pharma Mar S A Pharmar Procedimiento de obtencion de nuevos areno (e)indoles utiles como intermedios en la sintesis de productos con actividad antitumoral.
US5580871A (en) 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
GB9302046D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
GB9302044D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Cytotoxic compounds i
US6274551B1 (en) 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
US5569757A (en) 1993-03-30 1996-10-29 Rinehart; Kenneth L. 9-deazaadenosine and its 5'-α-D-glycopyranoside isolated from the cyanobacterium anabaena affinis strain VS-1
GB9308111D0 (en) 1993-04-20 1993-06-02 Pharma Gen S A Active compound from a stonge
US5556777A (en) 1993-09-09 1996-09-17 Pharmamar, S.A. Immunosuppressive pharmaceutical compositions new biological activity from a marine agrobacterium sp.
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US5514708A (en) 1994-02-18 1996-05-07 Pharmamar, S.A. Cytotoxic metabolites from Myriapora truncata
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5681813A (en) 1994-04-06 1997-10-28 Pharma Mar, S.A. Thiodepsipeptide isolated from a marine actinomycete
ES2100124B1 (es) 1994-08-01 1998-04-01 Pharma Mar Sa Perfeccionamientos introducidos en la p.i. 9401697 por terpeno-quinonas con actividad antitumoral.
US5514705A (en) 1994-09-07 1996-05-07 Pharmamar, S.A. Epidioxymanadic acids A and B
US5523456A (en) 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB9422946D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Antineoplastic cyclolignan derivatives
GB9422947D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Immunosuppressive cyclolignan derivatives
GB9504662D0 (en) 1995-03-08 1995-04-26 Pharma Mar Sa Antitumour isocoumarins
US20010039041A1 (en) 1995-06-07 2001-11-08 Pharma Mar, S.A. Immunosuppressive sesbanimide compositions and methods of treatment using same
US5661175A (en) 1995-06-20 1997-08-26 Kashman; Yoel Hemiasterlin and geodiamolide TA
US5852033A (en) 1995-06-29 1998-12-22 Pharma Mar, S.A. Methods of treatment using lamellarin-class alkaloids
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
US5681847A (en) 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
EP0821068A3 (fr) 1996-03-29 1999-06-02 Rohm And Haas Company Sphinogolipides et procédé pour ceux-ci
GB9608010D0 (en) 1996-04-18 1996-06-19 Pharma Mar Sa Trunkamide A
US6156724A (en) 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
WO1998017302A1 (fr) 1996-10-24 1998-04-30 The Board Of Trustees Of The University Of Illinois Synthese totale d'analogues amino-hip de didemnine a
CA2269881A1 (fr) 1996-10-24 1998-04-30 The Board Of Trustees Of The University Of Illinois Procedes semi-synthetiques de preparation d'analogues de didemnine
GB9622427D0 (en) 1996-10-28 1997-01-08 Pharma Mar Sa Antimalarial drugs
US6034058A (en) 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
USRE38793E1 (en) 1997-04-15 2005-09-06 Rinehart Kenneth L Spisulosine compounds
US6800661B1 (en) 1997-04-15 2004-10-05 Board Of Trustees Of The University Of Illinois Spisulosine compounds
US6107520A (en) 1997-04-15 2000-08-22 The Board Of Trustees Of The University Of Illinois Spisulosine compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
US6028077A (en) 1997-04-15 2000-02-22 Rinehart; Kenneth L. Crambescidin compounds
AUPO656597A0 (en) 1997-05-02 1997-05-29 Australian National University, The Preparation of therapeutic compounds
JP4327260B2 (ja) 1997-05-07 2009-09-09 フアルマ・マル・エセ・ア Ｌ型カルシウムチャンネルエンハンサーとしてのアプリジン
GB9723206D0 (en) 1997-11-03 1998-01-07 Inst Biomar Sa New cytotoxic pyridoacridine alkaloids
US6420357B1 (en) 1997-12-23 2002-07-16 Instituto Biomar, S.A. Cytotoxic alkaloid derivatives including Asmarine A and B isolated from a sponge
GB9727301D0 (en) 1997-12-23 1998-02-25 Inst Biomar Sa Asmarine A and B: New cytotoxic alkaloids
GB9801741D0 (en) 1998-01-27 1998-03-25 Inst Biomar Sa New cytotoxic tris (oxazole)-containing macrolides
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
IL138856A0 (en) 1998-04-06 2001-10-31 Univ Illinois Semi-synthetic ecteinascidins
US6656948B2 (en) 1998-04-29 2003-12-02 Universidad Complutense De Madrid Cytotoxic compounds: derivatives of the pyrido[2,3,4-kl]acridine ring system
TR200003257T2 (tr) 1998-05-05 2001-03-21 Graham Keith Ruffles Yerleşmiş deniz hayvanları kültürü.
JP4583598B2 (ja) * 1998-05-11 2010-11-17 ファルマ・マール・ソシエダード・アノニマ エクテイナシジン７４３の代謝産物
GB9810998D0 (en) 1998-05-21 1998-07-22 Univ Madrid Complutense Antitumour 1,5-diazaanthraquinones
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
GB9821975D0 (en) 1998-10-08 1998-12-02 Pharma Mar Sa New cytotoxic alkaloids
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
GB9918178D0 (en) 2000-05-15 1999-10-06 Pharma Mar Sa Synthetic methods
GB9915069D0 (en) 1999-06-28 1999-08-25 Inst Biomar Sa New indolocarbazole alkaloids from a marine actinomycete
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
SI1229922T1 (sl) 1999-11-15 2008-04-30 Pharma Mar Sa Zdravljenje raka z aplidinom
AU783562B2 (en) 2000-01-19 2005-11-10 Trustees Of Columbia University In The City Of New York, The Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
MXPA02007995A (es) 2000-02-16 2003-05-23 Ruffles Graham Keith Derivados de tetrahidrofurilo sustituidos por oxy y amino con actividad antitumoral.
US20030187075A1 (en) 2000-03-20 2003-10-02 Junichi Tanaka Keith Sponge antitumor compounds
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
AU2001251498A1 (en) 2000-04-07 2001-10-23 The Trustees Of The University Of Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
US7919493B2 (en) 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
DK1280809T3 (da) 2000-04-12 2005-11-07 Pharma Mar Sa Antitumorecteinascidinderivater
GB0010799D0 (en) 2000-05-04 2000-06-28 Inst Biomar Sa Stolonoxides
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
GB0011927D0 (en) 2000-05-17 2000-07-05 Inst Biomar Sa New use of citreamicins
EP1287006B1 (fr) 2000-06-06 2007-10-24 Pharma Mar, S.A. Nouveaux composes antitumoraux
GB0016020D0 (en) 2000-06-29 2000-08-23 Inst Biomar Sa New polyciclic xanthones and their use
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
ES2327210T3 (es) 2000-07-11 2009-10-27 Pharma Mar, S.A. Derivados de variolina como agentes anticancerigenos.
US6635054B2 (en) 2000-07-13 2003-10-21 Transurgical, Inc. Thermal treatment methods and apparatus with focused energy application
GB0019117D0 (en) 2000-08-03 2000-09-27 Univ Barcelona Derivatives of variolin B
CN1479622A (zh) 2000-10-12 2004-03-03 联合使用阿普里汀和肌肉保护剂来治疗癌症
MXPA03003230A (es) 2000-10-12 2004-12-03 Pharma Mar Sa Tratamiento de canceres.
NZ525243A (en) 2000-10-31 2005-01-28 Pharma Mar S A lyophilised formulation comprising kahalalide F, a peptide isolated from a herbivorous marine species of mollusc, Elysia rufescens, to treat cancer
NZ525730A (en) 2000-11-06 2004-12-24 Pharma Mar S Compositions for antitumour treatments containing Ecteinascidin 743
GB0030417D0 (en) 2000-12-13 2001-01-24 Pharma Mar Sa An anticancer lead compound isolated from a New Zealand ascidian
JP2004521112A (ja) 2001-01-24 2004-07-15 メステックス アクチエンゲゼルシャフト 関節痛治療薬を製造することへの神経毒性物質の使用
BR0206511A (pt) 2001-01-25 2003-10-21 Bristol Myeres Squibb Company Formulação parenteral para análogos de epotilona
EP1360337A1 (fr) 2001-02-09 2003-11-12 The Regents Of The University Of California Composes de la famille de l'ecteinascidine: compositions et procedes
GB0105745D0 (en) 2001-03-08 2001-04-25 Pharma Gen S A Immobilisation of ligands
GB0108234D0 (en) 2001-04-02 2001-05-23 Pharma Mar Sa Process for producing trunkamide A compounds
GB0116966D0 (en) 2001-07-11 2001-09-05 Pharma Mar Sa Anittumoral compounds
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
EP1435991B1 (fr) 2001-10-19 2008-10-15 Pharma Mar, S.A. Utilisation d'aplidine pour le traitement du cancer du pancreas
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
AU2002334203C1 (en) 2001-10-19 2008-10-09 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy
US20050004018A1 (en) 2001-10-19 2005-01-06 Jose Jimeno Use of antitumoral compound in cancer therapy
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0217638D0 (en) 2002-07-30 2002-09-11 Pharma Mar Sa Total synthesis of myriaporones
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
GB0218816D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa Antitumoral analogs of lamellarins
GB0218813D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa DNA sequences from an endosymbiont and their uses
US20040033940A1 (en) 2002-08-16 2004-02-19 Pharma Mar, S.A. Cyclic hepta-peptide derivative from colonial ascidians, lissoclinum SP
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
CN101077885A (zh) 2002-10-18 2007-11-28 马尔药品公司 新型抗肿瘤化合物
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
GB0303940D0 (en) 2003-02-20 2003-03-26 Pharma Mar Sau Solid phase synthesis of antitumoral compounds
ES2347959T3 (es) 2003-02-20 2010-11-26 Seattle Genetics, Inc. Conjugados de anticuerpos anti-cd70-farmaco y su uso para el tratamiento del cancer.
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
JP2006519848A (ja) 2003-03-12 2006-08-31 ファルマ・マール・ソシエダード・アノニマ 改良された抗腫瘍治療
AU2004218883B2 (en) 2003-03-12 2009-10-01 Dana-Farber Cancer Institute, Inc. Aplidine for multiple myeloma treatment
JP2006523214A (ja) 2003-03-21 2006-10-12 ジユーリー，マデレーン・エム タマンダリン類似物およびこれらのフラグメントそして製造方法および使用方法
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
EP1639090A4 (fr) 2003-06-09 2008-04-16 Univ Michigan Compositions et methodes de traitement et de diagnostic du cancer
GB0314726D0 (en) 2003-06-24 2003-07-30 Inst Biomar Sa New cytotoxic depsipeptides
EP1651633A1 (fr) 2003-07-25 2006-05-03 Novartis AG Lactames substitues et utilisation de ceux-ci en tant qu'agents anti-cancereux
GB0321066D0 (en) 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
WO2005035524A1 (fr) 2003-10-09 2005-04-21 Abbott Laboratories Derives de pyrrolidinyle- uree utilises comme inhibiteurs de l'angiogenese
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
JP2007511499A (ja) 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
DE102004011809A1 (de) 2004-03-11 2005-09-29 Robert Bosch Gmbh Magnetsensoranordnung
GB0408958D0 (en) 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
WO2005118584A2 (fr) 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Nouveaux analogues de saframycine utilises en tant qu'agents therapeutiques
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
JP2008505862A (ja) 2004-07-09 2008-02-28 ファルマ、マール、ソシエダード、アノニマ 予後分子マーカー
CA2583464A1 (fr) 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Agents anti-inflammatoires
EP1827500B1 (fr) 2004-10-26 2009-05-06 Pharma Mar S.A., Sociedad Unipersonal Doxorubicine liposomiale pegylee en combinaison avec l' ecteinescidine 743
PL1658848T3 (pl) 2004-10-29 2007-12-31 Pharma Mar Sa Preparaty zawierające ekteinascydynę i disacharyd
JP4993645B2 (ja) 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド 抗体薬剤結合体および方法
WO2006066183A2 (fr) 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Nouveaux analogues de saframycine utilises en tant qu'agents therapeutiques
EP1879870A1 (fr) 2005-05-03 2008-01-23 Pharma Mar, S.A. Tétrahydropyrimidines à effet antitumoral
GB0515673D0 (en) 2005-08-01 2005-09-07 Pharma Mar Sa Antitumoral compounds
JP2009502187A (ja) 2005-08-02 2009-01-29 ファルマ、マール、ソシエダード、アノニマ チオコラリンの生合成に関与する遺伝子およびその異種産生
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
GB0523098D0 (en) 2005-11-14 2005-12-21 Pharma Mar Sa Antitumoral compounds
US20090170860A1 (en) 2005-11-25 2009-07-02 Pharma Mar, S.A., Sociedad Unipersonal Use of PARP-1 Inhibitors
ES2276629B1 (es) 2005-12-15 2009-04-01 Pharma Mar, S.A. Compuestos antitumorales.
ES2288107B1 (es) 2006-01-27 2008-11-01 Fundacion Imabis Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanita Derivados aciclicos saturados e insaturados de cadena larga de sulfamidas como activadores especificos de receptores ppar-alfa.
US8258098B2 (en) 2006-02-28 2012-09-04 Pharma Mar, S.A. Antitumoral treatments
MX2008014404A (es) 2006-05-12 2008-11-27 Pharma Mar Sa Tratamientos anticancer con combinacion de docetaxel y ecteinascidin.
EP1864682A1 (fr) 2006-06-09 2007-12-12 Sanofi-Aventis Dérivés de la Leptomycine
EP2032551B9 (fr) 2006-06-16 2012-02-29 Pharma Mar, S.A. Composés de dihydropyran-2-one anticancéreux
CA2703026A1 (fr) 2007-10-19 2009-04-23 Rafael Rosell Costa Marqueurs moleculaires pronostiques pour le traitement par et-743
US20100240595A1 (en) 2007-10-19 2010-09-23 Pharma Mar ,S.A. Improved Antitumoral Treatments
WO2009052379A2 (fr) 2007-10-19 2009-04-23 Pharma Mar, S.A. Traitements antitumoraux améliorés
WO2009077401A1 (fr) 2007-12-14 2009-06-25 Pharma Mar, S.A. Composés antitumoraux
DK2231590T3 (da) 2007-12-20 2012-07-09 Pharma Mar Sa Antitumorforbindelser
AU2009209541A1 (en) 2008-01-30 2009-08-06 Pharma Mar, S.A. Improved antitumoral treatments
WO2009111698A1 (fr) 2008-03-07 2009-09-11 Pharma Mar, S.A. Traitements améliorés contre le cancer
EP2262522A1 (fr) 2008-03-07 2010-12-22 Pharma Mar, S.A. Traitements anti-tumoraux améliorés
NZ589270A (en) 2008-05-16 2011-12-22 Pharma Mar Sa Multiple myeloma treatments
NZ589269A (en) 2008-05-16 2013-03-28 Pharma Mar Sa Combination therapy with an antitumor alkaloid
PT3216793T (pt) 2008-05-23 2019-05-30 Wyeth Llc Compostos de triazina como inibidores de pi3 quinase e mtor
KR20110043653A (ko) 2008-07-03 2011-04-27 파르마 마르 에스.에이. 항종양 마크롤라이드
KR101667062B1 (ko) 2008-07-15 2016-10-17 제넨테크, 인크. 안트라시클린 유도체 접합체, 그의 제조 방법 및 항-종양 화합물로서의 그의 용도
RU2011105801A (ru) 2008-07-17 2012-08-27 Фарма Мар, С.А. (Es) Противораковые соединения
AU2009329517A1 (en) 2008-12-19 2011-06-23 Pharma Mar, S.A. Anticancer compounds
WO2010149688A2 (fr) 2009-06-24 2010-12-29 Pharma Mar, S.A. Composés anticancéreux
SI2563803T1 (sl) 2010-04-27 2016-06-30 Pharma Mar S.A. Na položaju 7 (8) nenasičeni steroidni lakton proti raku
CA2800097C (fr) * 2010-05-25 2019-01-08 Pharma Mar, S.A. Procede synthetique de fabrication de composes d'exteinascidine et d'intermediaires
TR201903859T4 (tr) 2010-11-12 2019-04-22 Pharma Mar Sa Bir antitümör antibiyotik ile kombinasyon terapisi.
DE102012211024A1 (de) 2012-06-27 2014-01-02 Robert Bosch Gmbh Verfahren zum Betreiben eines Fahrzeuges
JP5922518B2 (ja) 2012-07-20 2016-05-24 浜松ホトニクス株式会社 シンチレータパネル及び放射線検出器
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
EP3484876A1 (fr) 2016-07-14 2019-05-22 Pfizer Inc Nouveaux pyrimidine carboxamides utilisées comme inhibiteurs de l'enzyme vanin-1
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物

Also Published As

Publication number Publication date
JP2018188432A (ja) 2018-11-29
SG11201909841RA (en) 2019-11-28
CY1121884T1 (el) 2020-10-14
TW202202509A (zh) 2022-01-16
MX2019012812A (es) 2020-01-14
KR102510975B1 (ko) 2023-03-16
CL2019003057A1 (es) 2020-02-21
AU2018260314B2 (en) 2021-12-09
JP2018188431A (ja) 2018-11-29
TW202344509A (zh) 2023-11-16
US11713325B2 (en) 2023-08-01
SI4101855T1 (sl) 2024-03-29
HUE062157T2 (hu) 2023-10-28
EP4101855B1 (fr) 2023-08-02
EP3395820A1 (fr) 2018-10-31
US20210246146A1 (en) 2021-08-12
US10538535B2 (en) 2020-01-21
SI3395821T1 (sl) 2019-09-30
HUE046109T2 (hu) 2020-02-28
ES2960063T3 (es) 2024-02-29
EP3395821B1 (fr) 2019-05-15
US20210070775A1 (en) 2021-03-11
MX2021016058A (es) 2022-02-03
KR20220109495A (ko) 2022-08-04
AU2022200250B1 (en) 2022-02-10
PL4047002T3 (pl) 2023-07-24
WO2018197663A1 (fr) 2018-11-01
TWI807411B (zh) 2023-07-01
RS64686B1 (sr) 2023-11-30
PL3395820T3 (pl) 2019-11-29
PL4101855T3 (pl) 2023-12-27
AU2022200250C1 (en) 2022-06-23
MY198004A (en) 2023-07-25
FI3615544T3 (fi) 2023-05-23
ZA201907119B (en) 2021-07-28
DK4047002T3 (da) 2023-05-01
MD3615544T2 (ro) 2023-08-31
FI4047002T3 (fi) 2023-05-22
DK3395821T3 (da) 2019-08-19
KR102491180B1 (ko) 2023-01-20
SI3615544T1 (sl) 2023-07-31
IL295044B2 (en) 2023-11-01
CN117865987A (zh) 2024-04-12
MD4101855T2 (ro) 2023-12-31
US11339180B2 (en) 2022-05-24
KR102492283B1 (ko) 2023-01-27
IL295044A (en) 2022-09-01
MA44021A (fr) 2019-05-15
PT3395820T (pt) 2019-08-07
ES2740073T3 (es) 2020-02-05
ME03467B (fr) 2020-01-20
US20180312529A1 (en) 2018-11-01
DK4101855T3 (da) 2023-11-06
JP6501946B2 (ja) 2019-04-17
MA44020A (fr) 2018-10-31
HRP20231233T1 (hr) 2024-01-19
TWI742273B (zh) 2021-10-11
ES2741901T3 (es) 2020-02-12
PH12019550224A1 (en) 2020-10-12
AU2022201657A1 (en) 2022-03-31
BR112019022282A2 (pt) 2020-05-19
JP2020517709A (ja) 2020-06-18
KR20200012846A (ko) 2020-02-05
KR20210126791A (ko) 2021-10-20
IL295044B1 (en) 2023-07-01
US20220242883A1 (en) 2022-08-04
HRP20230433T1 (hr) 2023-07-07
IL270153B2 (en) 2023-10-01
SI4047002T1 (sl) 2023-07-31
US20240166666A1 (en) 2024-05-23
DK3615544T3 (da) 2023-05-30
RS59174B1 (sr) 2019-10-31
CN114736219A (zh) 2022-07-12
MD3395820T2 (ro) 2019-10-31
HK1255941B (zh) 2020-04-29
DK3395820T3 (da) 2019-08-12
EP3395820B1 (fr) 2019-05-15
JP2022130682A (ja) 2022-09-06
PT3395821T (pt) 2019-08-27
EP3395821A1 (fr) 2018-10-31
HRP20191443T1 (hr) 2019-11-15
UY37706A (es) 2018-11-30
AU2018260314A1 (en) 2019-10-31
LT4101855T (lt) 2023-08-25
CN110621678A (zh) 2019-12-27
EP3615544B1 (fr) 2023-03-22
ES2944579T3 (es) 2023-06-22
CN114736219B (zh) 2024-06-07
IL289963A (en) 2022-03-01
TN2019000211A1 (en) 2021-01-07
SI3395820T1 (sl) 2019-09-30
HUE063736T2 (hu) 2024-01-28
TW201906850A (zh) 2019-02-16
IL289963B2 (en) 2023-10-01
AU2018260314C1 (en) 2022-04-21
RS59173B1 (sr) 2019-10-31
EP4101855B9 (fr) 2024-01-03
EP4047002A1 (fr) 2022-08-24
HUE062032T2 (hu) 2023-09-28
CY1126061T1 (el) 2023-11-15
HRP20191442T1 (hr) 2019-11-15
MA44021B1 (fr) 2019-08-30
LT3615544T (lt) 2023-05-10
ECSP19083967A (es) 2019-12-27
JP2023052597A (ja) 2023-04-11
RS64174B1 (sr) 2023-05-31
HK1255938B (zh) 2020-04-29
MD4047002T2 (ro) 2023-08-31
MA44020B1 (fr) 2019-08-30
MD3395821T2 (ro) 2019-10-31
JOP20190254A1 (ar) 2019-10-27
US11332480B2 (en) 2022-05-17
PL3395821T3 (pl) 2019-10-31
EP4101855A1 (fr) 2022-12-14
AU2022200249B1 (en) 2022-02-10
TN2019000210A1 (en) 2021-01-07
JP7422812B2 (ja) 2024-01-26
EP3615544A1 (fr) 2020-03-04
JP6501947B2 (ja) 2019-04-17
ES2944344T3 (es) 2023-06-20
CO2019011967A2 (es) 2020-02-18
LT3395821T (lt) 2019-08-12
AU2022200249C1 (en) 2022-06-23
CN114751920A (zh) 2022-07-15
IL270153A (fr) 2019-12-31
HRP20230455T1 (hr) 2023-07-21
RS64200B1 (sr) 2023-06-30
CN114751920B (zh) 2024-06-07
IL289963B1 (en) 2023-06-01
LT3395820T (lt) 2019-08-12
EP3615544B9 (fr) 2024-01-03
CA3061518A1 (fr) 2018-11-01
JP7186723B2 (ja) 2022-12-09
PL3615544T3 (pl) 2023-07-17
IL270153B1 (en) 2023-06-01
ME03466B (fr) 2020-01-20
MX2021016054A (es) 2022-06-01
FI4101855T3 (fi) 2023-09-22
CY1121885T1 (el) 2020-10-14
EP4047002B1 (fr) 2023-03-08
HUE045641T2 (hu) 2020-01-28
JP7490835B2 (ja) 2024-05-27
LT4047002T (lt) 2023-05-10

Similar Documents

Publication Publication Date Title
GB201700814D0 (en) Compounds
GB201704327D0 (en) Compounds
GB201704325D0 (en) Compounds
IL289963A (en) Antitumor compounds
GB201702221D0 (en) Compounds
HUE058661T2 (hu) Morfolinilpiridon vegyületek
GB201703282D0 (en) Compounds
PT4047002T (pt) Compostos antitumorais
GB201708848D0 (en) Compounds
GB201706323D0 (en) Compounds
GB201703737D0 (en) Compounds
GB201703283D0 (en) Compounds
GB201703273D0 (en) Compounds
GB201703272D0 (en) Compounds